What angina is  Symptoms of angina The different types of angina  Its risk factors How it's diagnosed The treatments ...

The goals of treatment are to decrease the frequency of angina, increase longevity, and improve patients' QOL. Management of risk factors is an essential component of this therapy. Also important ...

The severity of symptoms varies for these types of angina. Stable angina, or angina pectoris, is chest pain or discomfort caused by heart disease. This results from one or more of the heart's ...

Cardiovascular diseases including myocardial infarction (MI), angina pectoris, stroke, heart failure (HF) and atrial fibrillation (AF). They also find the importance of tailoring CVD prevention and ...

Symptoms of PH include fatigue, lightheadedness, falls, visual blurring, syncope, transient ischemic attack, neck and lower back pain, calf claudication, and angina pectoris. Changing, stopping ...

Commercial launch of neffy®(epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by ...

To reduce combined risk of death and nonfatal MI after MI or unstable angina pectoris. To reduce combined risk of MI and sudden death in chronic stable angina. Revascularization procedures.

A look into gestational diabetes and its effect on long-term cardiovascular health for the beginning of Diabetes Awareness ...

Nicotine 7mg/24hr, 14mg/24hr, 21mg/24hr; transdermal patch (clear or original color). Avoid immediately post-MI, in arrhythmias, or severe or worsening angina pectoris. Uncontrolled hypertension.

The CVD outcomes considered by Schürks et al. included stroke, myocardial infarction, angina pectoris, and death due to CVD. Where possible, these outcomes were analyzed separately by aura status.

Detailed price information for Ars Pharmaceuticals Inc (SPRY-Q) from The Globe and Mail including charting and trades.

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...